
Gustavo Alva MD DFAPA
Founder and Medical Director of ATP Clinical Research
Join to View Full Profile
302 W La Veta Ave Ste 202Orange, CA 92866
Phone+1 714-545-5550
Fax+1 714-545-5748
Dr. Alva is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (Irvine)Residency, Psychiatry, 1994 - 1998
Universidad Autonoma de GuadalajaraClass of 1990
Certifications & Licensure
CA State Medical License 1995 - 2027
TX State Medical License 2017 - 2026
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
- A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease Start of enrollment: 2017 May 09
- Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Start of enrollment: 2022 Nov 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Developing Topics.Christopher M Duma, Hans Keirstead, Gabriel Nistor, Robert Lynn, Jessica J Buxton
Alzheimer's & Dementia. 2025-12-01 - Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study.Wiesław J Cubała, Ana Berrio, Katherine Chi-Burris, Gustavo Alva, Lambros Chrones
Journal of Alzheimer's Disease. 2025-07-01 - 2 citationsManagement of Parkinson's disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching.Stuart H Isaacson, Henry Nasrallah, Rajesh Pahwa, Gustavo Alva, Daniel Kremens
Expert Opinion on Pharmacotherapy. 2025-04-01
Press Mentions
Regeneration Biomedical’s Cell Therapy Reduces Tau, Boosts Cognition in Alzheimer’s CasesMay 6th, 2025
(6-Month Paliperidone Palmitate), First and Only Twice-Yearly Treatment for Adults with SchizophreniaSeptember 1st, 2021
Dollars for Docs Mints a MillionaireMarch 11th, 2013
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:








